Lantheus, a Massachusetts-based developer of radiopharmaceuticals, has agreed to acquire the radiopharma contract development and manufacturing organization (CDMO) Evergreen Theragnostics. Lantheus ...

The deal includes an upfront payment of $250m, with the potential for an additional $752.5m in milestone payments.

Lantheus Holdings, Inc. (NASDAQ:LNTH) agreed to acquire Evergreen Theragnostics, Inc. in an all-cash transaction involving an ...

With the aim to add a “revenue generating CDMO arm,” Lantheus Holdings has bought New Jersey-based radiopharmaceutical ...

Lantheus Holdings Inc. is adding to its portfolio yet again, acquiring a clinical-stage radiopharmaceutical company in a deal ...

Lantheus Holdings is stepping up its game in the radiopharmaceutical space by acquiring Massachusetts-based Evergreen ...

Lantheus Holdings Inc., a radiopharmaceutical-focused company, has agreed to acquire Evergreen Theragnostics Inc., in an ...

Lantheus ( ($LNTH) ) has shared an update. On January 27, 2025, Lantheus Medical Imaging, a subsidiary of Lantheus Holdings, announced an ...

On a quest to carve out a spot as one of the nuclear medicine greats, Massachusetts-based radiopharmaceutical specialist ...

Lantheus (LNTH) announced a definitive agreement to acquire Evergreen Theragnostics in an all-cash transaction consisting of an upfront payment ...

Lantheus is acquiring radiopharmaceutical CDMO Evergreen Theragnostics in a deal worth up to $1 billion, expanding its manufacturing capabilities and drug pipeline. The acquisition includes Octevy, a ...